Coronavirus | COVAXIN could be launched as early as February: ICMR scientist

A scientist prepares samples during the research and development of a vaccine against the coronavirus disease. File   | Photo Credit: REUTERS

COVAXIN, the government-backed COVID-19 vaccine, could be launched as early as February — months earlier than expected — as last-stage trials begin this month and studies have so far showed it is safe and effective, a senior ICMR scientist told Reuters.

Bharat Biotech, which is developing COVAXIN with the Indian Council of Medical Research, had earlier hoped to launch it only in the second quarter of next year.

“The vaccine has shown good efficacy,” senior ICMR scientist Rajni Kant, who is also a member of the Centre’s COVID-19 task-force, said at the research body's headquarters in New Delhi on Thursday. “It is expected that by the beginning of next year, February or March, something would be available.”

Bharat Biotech could not immediately be contacted.

A launch in February would make COVAXIN the first India-made vaccine to be rolled out.

Dr. Kant, who is the head of ICMR's research management, policy, planning and coordination cell, said it was up to the Health Ministry to decide if COVAXIN shots can be given to people even before the third-stage trials are over.

“It has shown safety and efficacy in the phase 1 and 2 trials and in the animal studies - so it is safe but you can't be 100% sure unless the phase 3 trials are over,” Dr. Kant said. “There may be some risk, if you are ready to take the risk, you can take the vaccine. If necessary, the government can think of giving the vaccine in an emergency situation.”

Union Health Minister Harsh Vardhan said in September the government was considering granting an emergency authorisation for a COVID-19 vaccine, particularly for the elderly and people in high-risk workplaces.

Several leading vaccine candidates are already in final-stage testing. An experimental vaccine developed by Britain's AstraZeneca is among the most advanced ones, and Britain expects to roll it out in late December or early 2021.

AstraZeneca has signed several supply and manufacturing deals with companies and governments around the world, including with the Serum Institute of India.

Other late-stage vaccines are developed by Moderna Inc , Pfizer Inc with partner BioNTech SE, and Johnson & Johnson.

Our code of editorial values

This article is closed for comments.
Please Email the Editor

Printable version | Oct 24, 2021 7:28:40 PM |

Next Story